Posts
In todays's New York Times....
http://www.nytimes.com/2009/07/22/business/22biogenerics.html?emc=tnt&tntemail1=y
Wednesday, July 22, 2009
Subscribe to:
Post Comments (Atom)
Following the end of the extraordinary Pharmalot site...Wait a minute, Ed and Pharmalot are back! That is terrific. See our new "mission statement" below.
Are we a society that uses fellow human beings as a means to an end?
PharmaLittle - Top 100
Labels
- abortion (1)
- access to affordable drugs (1)
- accountability (1)
- acquisition (1)
- ADDA (1)
- ads (1)
- Advanced Medical Optics (1)
- Adverse Events (2)
- Alito (2)
- America's sick and poor (1)
- antipsychotic (1)
- approval (1)
- Astra Zeneca (1)
- Astra Zeneca FDA corruption burying studies (1)
- AstraZeneca (1)
- Australia (2)
- Autism (1)
- Avodart (1)
- back surgery (1)
- Bayer (1)
- benefits (1)
- Biederman (2)
- Bill (1)
- Bristol Myers Squibb (1)
- Buffet (1)
- Bush (1)
- Canada (1)
- cancer (1)
- CDC (1)
- CDER (1)
- Celexa (1)
- change agents (1)
- Chantix (1)
- Cheated (1)
- children (1)
- cigna (1)
- civil (1)
- CLASS (1)
- CME (1)
- COI (4)
- Commissioner Sharfstein (1)
- comparative efficacy (2)
- conflict of interest (3)
- Congress (8)
- congressional (1)
- Constitution (1)
- corruption (9)
- costs (1)
- cover-up (1)
- criminal (1)
- data (1)
- DDMAC (1)
- dead-enders (1)
- Death Panel (1)
- defibrillator (1)
- defrauding (1)
- Department of Justice (2)
- deregulation (2)
- Device (1)
- device manufacturers (2)
- DHHS (1)
- Diabetes (1)
- disaster (1)
- discredit (1)
- Dissent (1)
- divestment (1)
- Doctor (1)
- doctor gifts (3)
- doctors (1)
- DOJ (1)
- Drug and device accountability (1)
- Drug and device law (1)
- Drug Costs (1)
- drug industry immunity (1)
- drug labeling (1)
- drug prescribing incentives (1)
- Drug Prices (1)
- Drug reimportation (1)
- drug safety (2)
- Drugs (1)
- DTC (1)
- DTCA (1)
- Ed Silverman (2)
- Efficacy (1)
- Electroshock (1)
- Eli Lilly (1)
- Eprex fraud (1)
- Epstein (1)
- Eshenbach (1)
- ethics (1)
- Europe (1)
- failure to warn (1)
- FDA (38)
- FDA devices corruption politicans graft campaign Democrat (1)
- FDA Preemption (20)
- fear mongering (1)
- Fidelis (1)
- financial gain (1)
- Food (1)
- Forest (1)
- Franklin (2)
- fraud (1)
- FTC (1)
- fundraisers (1)
- Gang of Six (1)
- GAO (2)
- Gardasil (1)
- Gates (1)
- generics (1)
- Georgia (2)
- ghosts (1)
- Ghostwriting (1)
- Gifts (3)
- Gingrich (1)
- God (1)
- Graft (1)
- Grassley (2)
- GSK (1)
- Hamburg (4)
- harassment (1)
- Harvard (1)
- Harvard Medical Students (1)
- health care (2)
- Health Care Reform (2)
- health reform (3)
- healthcare (1)
- Healthcare Reform (2)
- heath care (1)
- hitlist (1)
- House (1)
- HR 1346/S 540 (1)
- HRT (1)
- illegal (1)
- influence peddling (1)
- insurance (1)
- insurance agency (1)
- Intellectual Bias (1)
- intimidation (1)
- investigation (1)
- J J whistleblower (1)
- JAMA (2)
- Januvia (1)
- JIM (1)
- Johnson and Johnson (1)
- Joshua Sharfstein (2)
- journals (2)
- Judge Kyle (1)
- Justice in Michigan (1)
- kickbacks (1)
- Law (1)
- lawsuits (1)
- Legal rights (1)
- letter (1)
- Levine (4)
- Lilly (3)
- Lobby (1)
- Lobbying (1)
- Lobbyists (1)
- long term patent protection (1)
- Max Baucus (1)
- media (1)
- Medical Device Preemption (4)
- Medical Device Safety Act (6)
- Medical Devices (13)
- Medicare (1)
- medicines (1)
- Medtronic (6)
- meeting (1)
- Merck (6)
- Merger (1)
- Michigan (8)
- military doctors (1)
- movie theaters (1)
- Mylan (2)
- NEJM (1)
- Neurontin (2)
- neutralise (1)
- new drugs (2)
- New England Journal of Medicine (2)
- Obama (5)
- Off Label (1)
- off-label promotion (2)
- Orrin Hatch (1)
- Orszag (1)
- over prescribing drugs (1)
- Overwarning (1)
- Paxil (2)
- payola (1)
- Peanut (1)
- Petco (1)
- Pfizer (7)
- Pharma (8)
- pharma gifts (1)
- Pharma Stock (1)
- pharmaceutical (2)
- pharmaceuticals (1)
- Pharmacia (1)
- Pharmalot (2)
- pharmaporn (1)
- Phillip Morris (1)
- PhRMA (5)
- Plan B (1)
- politicians (1)
- pornography (1)
- portfolio synergy (1)
- pre-emption (3)
- Preemption (21)
- preemption preamble (1)
- Prempro (1)
- Prescription (1)
- Procrit (1)
- ProDisc (1)
- promotion (1)
- Proscar (1)
- prostate (1)
- psychiatry bipolar (1)
- Reform (3)
- regulationj (1)
- religious belief's (1)
- reviewers (1)
- Riegel (4)
- rights (1)
- risks (1)
- Roberts (3)
- Safety (1)
- safety act (1)
- sales (1)
- Sanjay Gupta Surgeon General? (1)
- Sanofi Aventis (1)
- Schering-Plough (2)
- science (1)
- Senate (1)
- Seroquel (3)
- Seroquel AstraZeneca (1)
- Seth Harp (1)
- Sidney Wolfe (1)
- sociopathy (1)
- Sonny Perdue (1)
- stakeholders (1)
- Stevens (1)
- subpoena (1)
- Supreme Court (3)
- supressing (1)
- Synthes (1)
- Tauzin (2)
- tax payer dollars (1)
- Thomas (1)
- thought experiment (1)
- tobacco (2)
- Tort Reform (2)
- Troy (4)
- Tumas (1)
- twitter (1)
- U.S. Chamber of Commerce (1)
- U.S. House (1)
- Ultram (1)
- Underfunded (1)
- universal healthcare (1)
- Vaccine (2)
- Vioxx (4)
- Vladeck (1)
- warning letters (1)
- Washington Legal Foundation (1)
- Wasman (1)
- ways to cut health care costs (1)
- Whistle Blower (2)
- whistleblowers (3)
- WHO (1)
- womens health (1)
- Wyeth (6)
- Wyeth v. Levine (1)
While reading the link, all I could think of is that the promise of needed medication is being smashed by greed.
ReplyDelete“At issue are such drugs as Biogen Idec’s Avonex, for multiple sclerosis, which can cost more than $20,000 a year; Genentech’s Avastin for cancer, which can cost more than $50,000; and several Genzyme drugs for rare diseases that can cost $200,000 a year or more.”
These meds will definitely be reserved for the very rich whose insurance plans cover the drugs and who can afford the co-pays. Most patients in need will be left out. Is this really the best America can do?